RxDoctor Payments Data

Jonathan Charney, MD

Neurology · New York, NYNPI 1568593457

Payments from drug & device makers

$20,306in general payments, 2019–2025

Across 371 payments — averaging $54.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • AstraZeneca$1K
  • Biogen$1K
  • Amgen$1K
  • E.r. Squibb & Sons, L.L.C.$1K
  • Lundbeck LLC$894
  • plus $12K from 37 others

What the payments were for

  • Consulting fees$4502%
  • Speaking & faculty fees$5883%
  • Food & beverage$19,25395%
  • Education$160%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,306 in reported general payments places this provider in the 75th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$410,316
Medicare patients
476
Services billed
3,012

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OctagamImmun Globg(Igg)/Malt/Iga Ov5013$95,593
TecfideraDimethyl Fumarate11$93,973
RytaryCarbidopa/Levodopa25$12,422
Gabapentin419$8,018
AmantadineAmantadine Hcl141$6,062
Memantine Hcl67$3,349
Levetiracetam70$2,906
Butalbital-Acetaminophen-CaffeButalb/Acetaminophen/Caffeine22$2,816
Oxcarbazepine40$2,781
Carbidopa-LevodopaCarbidopa/Levodopa111$2,720
Zolmitriptan OdtZolmitriptan11$2,560
Donepezil Hcl160$2,242
Tizanidine Hcl150$2,153
Primidone108$1,851
Duloxetine Hcl59$1,583

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerOctagam$612$95,59313 claims
BiogenTecfidera$1,293$93,97311 claims
Amneal Pharmaceuticals LLCRytary$147$12,42225 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,623 neurology providers in New York.

Other neurology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →